AstraZeneca Aktie
WKN: 886715 / ISIN: US0463531089
25.06.2024 08:37:07
|
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
(RTTNews) - AstraZeneca (AZN.L, AZN) said high-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group, showed Imfinzi did not achieve statistical significance for the primary endpoint of disease-free survival versus placebo in early-stage non-small cell lung cancer after complete tumour resection in patients whose tumours express PD-L1 on 25% or more tumour cells. The safety profile for Imfinzi was consistent with its known safety profile.
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "We are disappointed in the ADJUVANT BR.31 results. We are committed to addressing the remaining unmet need in lung cancer through our broad development programme."
The company noted that Imfinzi is also being investigated as monotherapy and in combinations in several other early-stage lung cancer settings, including in medically inoperable or unresected Stage I-II NSCLC and unresectable, Stage III NSCLC.
For More Such Health News, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
14.04.25 |
NASDAQ 100-Papier AstraZeneca-Aktie: Über diese Dividende können sich AstraZeneca-Anleger freuen (finanzen.at) | |
14.04.25 |
Erste Schätzungen: AstraZeneca informiert über die jüngsten Quartalsergebnisse (finanzen.net) | |
11.04.25 |
Gute Stimmung in New York: NASDAQ 100 schlussendlich freundlich (finanzen.at) | |
11.04.25 |
Pluszeichen in New York: NASDAQ 100 verbucht nachmittags Gewinne (finanzen.at) | |
11.04.25 |
Börse New York: So steht der NASDAQ 100 aktuell (finanzen.at) | |
11.04.25 |
Aufschläge in New York: NASDAQ 100 verbucht zum Handelsstart Zuschläge (finanzen.at) | |
10.04.25 |
Schwacher Wochentag in New York: NASDAQ 100 schließt weit in der Verlustzone (finanzen.at) | |
10.04.25 |
Börse New York in Rot: NASDAQ 100-Anleger treten am Nachmittag Rückzug an (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 61,00 | 1,67% |
|